Trial · NCT03393754
Results by group24
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 24
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Seroprotection Rate (SPR) Defined as Percentage of Adults ≥ 18 Years Old Achieving Anti-HBs Levels of ≥10 mIU/mL in Serum at Study Day 196 | Engerix-B® Hepatitis B Vaccination | 76.49 | 95% Confidence Interval 73.22 to 79.53 | percentage of participants seroprotected | |
| Seroprotection Rate (SPR) Defined as Percentage of Adults ≥ 18 Years Old Achieving Anti-HBs Levels of ≥10 mIU/mL in Serum at Study Day 196 | Sci-B-Vac® Hepatitis B Vaccination | 91.36 | 95% Confidence Interval 89.07 to 93.32 | percentage of participants seroprotected | |
| Seroprotection Rate (SPR) Defined as Percentage of Adults ≥ 45 Years Old Achieving Anti-HBs Levels of ≥10 mIU/mL in Serum at Study Day 196 | Engerix-B® Hepatitis B Vaccination | 73.05 | 95% Confidence Interval 69.39 to 76.48 | percentage of participants seroprotected | |
| Seroprotection Rate (SPR) Defined as Percentage of Adults ≥ 45 Years Old Achieving Anti-HBs Levels of ≥10 mIU/mL in Serum at Study Day 196 | Sci-B-Vac® Hepatitis B Vaccination | 89.44 | 95% Confidence Interval 86.76 to 91.74 | percentage of participants seroprotected | |
| Percentage of Subject-reporting Solicited Local and Systemic Adverse Events (AEs) | Engerix-B® Hepatitis B Vaccination | Pain | 294 | Participants | |
| Percentage of Subject-reporting Solicited Local and Systemic Adverse Events (AEs) | Sci-B-Vac® Hepatitis B Vaccination | Pain | 503 | Participants | |
| Percentage of Subject-reporting Solicited Local and Systemic Adverse Events (AEs) | Engerix-B® Hepatitis B Vaccination | Tenderness | 282 | Participants | |
| Percentage of Subject-reporting Solicited Local and Systemic Adverse Events (AEs) | Sci-B-Vac® Hepatitis B Vaccination | Tenderness | 484 | Participants | |
| Percentage of Subject-reporting Solicited Local and Systemic Adverse Events (AEs) | Engerix-B® Hepatitis B Vaccination | Pruritus/itching | 66 | Participants | |
| Percentage of Subject-reporting Solicited Local and Systemic Adverse Events (AEs) | Sci-B-Vac® Hepatitis B Vaccination | Pruritus/itching | 76 | Participants | |
| Percentage of Subject-reporting Solicited Local and Systemic Adverse Events (AEs) | Engerix-B® Hepatitis B Vaccination | Redness/erythema | 15 | Participants | |
| Percentage of Subject-reporting Solicited Local and Systemic Adverse Events (AEs) | Sci-B-Vac® Hepatitis B Vaccination | Redness/erythema | 18 | Participants | |
| Percentage of Subject-reporting Solicited Local and Systemic Adverse Events (AEs) | Engerix-B® Hepatitis B Vaccination | Swelling/edema | 12 | Participants | |
| Percentage of Subject-reporting Solicited Local and Systemic Adverse Events (AEs) | Sci-B-Vac® Hepatitis B Vaccination | Swelling/edema | 18 | Participants | |
| Percentage of Subject-reporting Solicited Local and Systemic Adverse Events (AEs) | Engerix-B® Hepatitis B Vaccination | Fatigue | 249 | Participants | |
| Percentage of Subject-reporting Solicited Local and Systemic Adverse Events (AEs) | Sci-B-Vac® Hepatitis B Vaccination | Fatigue | 242 | Participants | |
| Percentage of Subject-reporting Solicited Local and Systemic Adverse Events (AEs) | Engerix-B® Hepatitis B Vaccination | Headache | 238 | Participants | |
| Percentage of Subject-reporting Solicited Local and Systemic Adverse Events (AEs) | Sci-B-Vac® Hepatitis B Vaccination | Headache | 249 | Participants | |
| Percentage of Subject-reporting Solicited Local and Systemic Adverse Events (AEs) | Engerix-B® Hepatitis B Vaccination | Myalgia | 197 | Participants | |
| Percentage of Subject-reporting Solicited Local and Systemic Adverse Events (AEs) | Sci-B-Vac® Hepatitis B Vaccination | Myalgia | 276 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03393754/results